Esperion Therapeutics (ESPR), Monday announced that it has entered into a license and distribution agreement with CSL Seqirus (CSL) to exclusively commercialize NEXLETOL and NEXLIZET in Australia and New Zealand.
Under the agreement, Esperion will receive upfront and milestone payments of upto $5 million and will supply the finished product to CSL Seqirus at a profitable transfer price.
With this deal, both companies expressed commitment to expanding access to treatments and addressing the burden of cardiovascular disease.
ESPR is currently trading pre-market at 1.73, up 1.76 percent or $0.03 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.